 Investigate whether switch from a non-nucleoside reverse transcriptase inhibitor NNRTI- or protease inhibitor PI-based regimen to a raltegravir-based regimen results in reduced platelet reactivity, reduced platelet-leukocyte aggregate formation and pro-inflammatory status of monocytes. 